{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:12:59Z","timestamp":1778850779069,"version":"3.51.4"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.resinv.2026.101436","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:54:45Z","timestamp":1777596885000},"page":"101436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pneumocystis jirovecii pneumonia in systemic rheumatic diseases: risk assessment and prophylaxis with emphasis on reduced-dose sulfamethoxazole\/trimethoprim"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-4149","authenticated-orcid":false,"given":"Shin-ichiro","family":"Ohmura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2026.101436_bib1","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1056\/NEJMc070728","article-title":"Pneumocystis pneumonia associated with infliximab in Japan","volume":"357","author":"Harigai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101436_bib2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.24283","article-title":"Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients","volume":"61","author":"Komano","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2026.101436_bib3","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/s10165-012-0615-z","article-title":"Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors","volume":"22","author":"Tanaka","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/s10165-005-0395-9","article-title":"Clinical characteristics of Pneumocystis carinii pneumonia in patients with connective tissue diseases","volume":"15","author":"Sato","year":"2005","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijid.2016.03.018","article-title":"Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients","volume":"46","author":"Bienvenu","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.resinv.2026.101436_bib6","first-page":"19","article-title":"Pneumocystis pneumonia in human immunodeficiency virus-infected adults and adolescents: current concepts and future directions","volume":"9","author":"Tasaka","year":"2015","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"10.1016\/j.resinv.2026.101436_bib7","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2169\/internalmedicine.47.0702","article-title":"Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study","volume":"47","author":"Tokuda","year":"2008","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2026.101436_bib8","first-page":"517","article-title":"Clinical characteristics and prognostic analysis of concurrent Pneumocystis jirovecii pneumonia in patients with connective tissue diseases: a retrospective study","volume":"44","author":"Shi","year":"2026","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2169\/internalmedicine.50.4508","article-title":"Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study","volume":"50","author":"Kameda","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2026.101436_bib10","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1080\/14397595.2018.1496873","article-title":"Rapid glucocorticoid tapering therapy to reduce mortality from pneumocystis pneumonia in patients with rheumatic disease","volume":"29","author":"Ando","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214324","article-title":"Prognostic factors of Pneumocystis pneumonia in patients with systemic autoimmune diseases","volume":"14","author":"Kageyama","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2026.101436_bib12","article-title":"Prognostic factors for mortality in patients with autoimmune diseases complicated by Pneumocystis pneumonia","volume":"16","author":"Shimizu","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.resinv.2026.101436_bib13","doi-asserted-by":"crossref","first-page":"7399","DOI":"10.3390\/ijms24087399","article-title":"Prognostic factors affecting death in patients with rheumatoid arthritis complicated by Pneumocystis jirovecii pneumonia and one-year clinical course: the ANSWER cohort study","volume":"24","author":"Shiba","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.resinv.2026.101436_bib14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/mr\/roac088","article-title":"Outcomes and risk factors for mortality in Pneumocystis pneumonia patients with rheumatoid arthritis: a multicentre retrospective cohort study","volume":"33","author":"Mori","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib15","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00296-009-0857-z","article-title":"Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases","volume":"29","author":"Aoki","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.resinv.2026.101436_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.resinv.2024.02.015","article-title":"Comparison of the outcomes of Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients treated with and without biologics","volume":"62","author":"Ohmura","year":"2024","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2026.101436_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jiac.2018.11.014","article-title":"Effectiveness and safety of lower dose sulfamethoxazole\/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: a retrospective multicenter study","volume":"25","author":"Ohmura","year":"2019","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.resinv.2026.101436_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005590.pub2","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","author":"Green","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.resinv.2026.101436_bib19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","article-title":"Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality","volume":"42","author":"Ward","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2026.101436_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11926-017-0664-6","article-title":"Pneumocystis pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented?","volume":"19","author":"Wolfe","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.resinv.2026.101436_bib21","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1007\/s10067-021-05660-4","article-title":"Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study","volume":"40","author":"Hsu","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib22","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/mr\/roac124","article-title":"Chemoprophylaxis against pneumocystis jirovecii pneumonia in Japanese patients with ANCA-Associated vasculitis: an observational study","volume":"33","author":"Nakaya","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib23","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s10067-018-4155-6","article-title":"Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis","volume":"37","author":"Metraiah","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/ard-2023-224472","article-title":"Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database","volume":"83","author":"Ishikawa","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2026.101436_bib25","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/acr.25222","article-title":"Incidence of pneumocystis jiroveci pneumonia in patients with ANCA-associated vasculitis initiating therapy with rituximab or cyclophosphamide","volume":"76","author":"Nettleton","year":"2024","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.resinv.2026.101436_bib26","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American college of Rheumatology\/Vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13075-024-03434-2","article-title":"Clinical practice pattern of Pneumocystis pneumonia prophylaxis in systemic lupus erythematosus: a cross-sectional study from lupus registry of nationwide institutions (LUNA)","volume":"26","author":"Onishi","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.resinv.2026.101436_bib28","first-page":"47","article-title":"Incidence of Pneumocystis jirovecii pneumonia and prophylaxis-associated adverse events among patients with systemic lupus erythematosus","volume":"52","author":"Jiang","year":"2025","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib29","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/acr.24584","article-title":"Pneumocystis jirovecii pneumonia in systemic lupus erythematosus: a nationwide cohort study in Taiwan","volume":"74","author":"Wang","year":"2022","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.resinv.2026.101436_bib30","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1177\/09612033211033985","article-title":"Adverse drug reactions to trimethoprim-sulfamethoxazole in systemic lupus erythematosus","volume":"30","author":"Izuka","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.resinv.2026.101436_bib32","first-page":"210","article-title":"Analysis of clinical features and risk factors for patients with idiopathic inflammatory myopathy complicated by Pneumocystis jirovecii pneumonia","volume":"44","author":"Li","year":"2026","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib33","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1093\/rheumatology\/kead034","article-title":"Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with anti-melanoma differentiation-associated gene 5","volume":"62","author":"Liu","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101436_bib34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13075-021-02606-8","article-title":"High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center","volume":"23","author":"Huang","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"10.1016\/j.resinv.2026.101436_bib35","first-page":"29","article-title":"Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients: risks and prophylaxis recommendations","volume":"9","author":"Mori","year":"2015","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"10.1016\/j.resinv.2026.101436_bib36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.resinv.2017.01.002","article-title":"Consensus statements for medical practice: biological agents and lung disease (abridged English translation by the Japanese respiratory society)","volume":"55","author":"Tokuda","year":"2017","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2026.101436_bib37","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2169\/internalmedicine.8205-21","article-title":"Factors associated with Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving methotrexate: a single-center retrospective study","volume":"61","author":"Ohmura","year":"2022","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2026.101436_bib38","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","volume":"2014","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.resinv.2026.101436_bib39","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/acr.21857","article-title":"Recent-onset systemic lupus erythematosus complicated by acute respiratory failure","volume":"65","author":"Demoruelle","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.resinv.2026.101436_bib40","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/archinte.1995.00430110015002","article-title":"Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: more patients, same risk","volume":"155","author":"Sepkowitz","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.resinv.2026.101436_bib41","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/339548","article-title":"Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome","volume":"34","author":"Sepkowitz","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2026.101436_bib42","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2026.101436_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13075-019-1996-6","article-title":"Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids: clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.resinv.2026.101436_bib44","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2026.101436_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/14397595.2018.1532483","article-title":"Safety and effectiveness of high-dose methotrexate (over 8 mg\/week) in 2838 Japanese patients with rheumatoid arthritis: a postmarketing surveillance report","volume":"30","author":"Suzuki","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib46","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/rheumatology\/kez349","article-title":"The association between lymphopenia and serious infection risk in rheumatoid arthritis","volume":"59","author":"Subesinghe","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101436_bib47","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3109\/14397595.2015.1118196","article-title":"Possible preventive effect of salazosulfapyridine against development of Pneumocystis pneumonia in methotrexate-receiving patients with rheumatoid arthritis","volume":"26","author":"Mizushina","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.70318","article-title":"Risk factors for Pneumocystis jirovecii pneumonia in rheumatoid arthritis: the protective potential of salazosulfapyridine","volume":"28","author":"Hara","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.resinv.2026.101436_bib49","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jiac.2022.10.019","article-title":"Efficacy of sulfasalazine for the prevention of Pneumocystis pneumonia in patients with rheumatoid arthritis: a multicentric self-controlled case series study","volume":"29","author":"Nunokawa","year":"2023","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.resinv.2026.101436_bib50","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185x.70516","article-title":"Risk of Pneumocystis pneumonia in patients with rheumatoid arthritis and the role of prophylactic salazosulfapyridine","volume":"28","author":"Sato","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.resinv.2026.101436_bib51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2026.101436_bib52","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3109\/s10165-012-0796-5","article-title":"Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients","volume":"23","author":"Watanabe","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib53","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.080791","article-title":"Postmarketing surveillance of the safety and effectiveness of etanercept in Japan","volume":"36","author":"Koike","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib54","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3109\/14397595.2013.843760","article-title":"Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients","volume":"24","author":"Koike","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib55","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/14397595.2017.1325058","article-title":"Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis","volume":"28","author":"Kanbori","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib56","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/mr\/roae019","article-title":"Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: up to 3-year results from a postmarketing surveillance study","volume":"34","author":"Kameda","year":"2024","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jmii.2024.08.013","article-title":"Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor","volume":"58","author":"Huang","year":"2025","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.resinv.2026.101436_bib58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan","volume":"41","author":"Koike","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib59","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/14397595.2015.1123211","article-title":"Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib60","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1002\/art.42541","article-title":"Risk-benefit analysis of primary prophylaxis against Pneumocystis jirovecii pneumonia in patients with rheumatic diseases receiving rituximab","volume":"75","author":"Park","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib61","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/mr\/road063","article-title":"Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: interim analysis of post-marketing surveillance","volume":"34","author":"Kuwana","year":"2024","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib62","article-title":"A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib","volume":"14","author":"Wu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.resinv.2026.101436_bib63","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/RHU.0000000000000731","article-title":"Risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis and a prophylactic indication of trimethoprim\/sulfamethoxazole","volume":"24","author":"Yukawa","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib64","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/14397595.2020.1812834","article-title":"The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of pneumocystis pneumonia in patients with rheumatic diseases","volume":"31","author":"Harada","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib65","article-title":"An open-label, randomized controlled trial of sulfamethoxazole-trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up","volume":"4","author":"Utsunomiya","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.resinv.2026.101436_bib66","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.resinv.2024.10.007","article-title":"Effectiveness and safety of lower dose sulfamethoxazole\/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in patients with systemic rheumatic diseases receiving moderate-to high-dose glucocorticoids","volume":"62","author":"Ohmura","year":"2024","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2026.101436_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-213027","article-title":"Can we prescribe TMP\/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?","volume":"78","author":"Suyama","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2026.101436_bib68","article-title":"Low-dose trimethoprim- sulfamethoxazole for prophylaxis of Pneumocystis jirovecii pneumonia in HIV-uninfected patients: a systematic review and meta-analysis","volume":"16","author":"Huang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.resinv.2026.101436_bib69","doi-asserted-by":"crossref","first-page":"142","DOI":"10.55563\/clinexprheumatol\/p34lkr","article-title":"Protective effect of different doses of trimethoprim-sulfamethoxazole prophylaxis for early severe infections among patients with antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"39","author":"Waki","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.resinv.2026.101436_bib70","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jiac.2019.01.005","article-title":"Efficacies of atovaquone, pentamidine, and trimethoprim\/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases","volume":"25","author":"Kitazawa","year":"2019","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.resinv.2026.101436_bib71","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00296-021-04945-w","article-title":"Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids","volume":"42","author":"Jinno","year":"2022","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.resinv.2026.101436_bib72","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.43167","article-title":"Clinical factors associated with Pneumocystis pneumonia despite its primary prophylaxis: when to stop prophylaxis?","volume":"77","author":"Kim","year":"2025","journal-title":"Arthritis Rheumatol"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526000705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526000705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:59:29Z","timestamp":1778849969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534526000705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2212534526000705"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101436","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumocystis jirovecii pneumonia in systemic rheumatic diseases: risk assessment and prophylaxis with emphasis on reduced-dose sulfamethoxazole\/trimethoprim","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101436"}}